# Ethosomal Gel Bearing Losartan 5% for Keloid Treatment

> **NCT05893108** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Yuni Eka Anggraini** · enrollment: 46 (estimated)

## Conditions studied

- Keloid

## Interventions

- **DRUG:** Ethosomal gel bearing losartan 5%
- **DRUG:** triamcinolone acetonide 10 mg/ml

## Key facts

- **NCT ID:** NCT05893108
- **Lead sponsor:** Yuni Eka Anggraini
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-30
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05893108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05893108, "Ethosomal Gel Bearing Losartan 5% for Keloid Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05893108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*